Technical Analysis for NEXI - NexImmune, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.22 | 5.77% | 0.01 |
NEXI closed down 17.79 percent on Tuesday, November 19, 2024, on approximately normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Resistance | Bearish | 5.77% | |
Fell Below 20 DMA | Bearish | 5.77% | |
Stochastic Reached Oversold | Weakness | 5.77% | |
Wide Bands | Range Expansion | 5.77% | |
Oversold Stochastic | Weakness | 5.77% | |
50 DMA Resistance | Bearish | -13.04% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -13.04% | |
Earnings Movers | Other | -13.04% | |
Wide Bands | Range Expansion | -13.04% | |
Fell Below 50 DMA | Bearish | -13.04% |
Alert | Time |
---|---|
Possible Inside Day | about 17 hours ago |
2x Volume Pace | about 21 hours ago |
1.5x Volume Pace | about 21 hours ago |
3x Volume Pace | about 21 hours ago |
Up 5% | about 21 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/15/2024
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The company has two product candidates in human trials, including NEXI-001 in acute myeloid leukemia, or AML; and NEXI-002 in multiple myeloma, or MM. NexImmune, Inc. was founded in 2011 and is headquartered in Gaithersburg, Maryland.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Acute Myeloid Leukemia Immunotherapies Leukemia Multiple Myeloma Immune Mediated Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Acute Myeloid Leukemia Immunotherapies Leukemia Multiple Myeloma Immune Mediated Diseases
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 28.6949 |
52 Week Low | 0.2 |
Average Volume | 3,284 |
200-Day Moving Average | 3.19 |
50-Day Moving Average | 0.28 |
20-Day Moving Average | 0.25 |
10-Day Moving Average | 0.24 |
Average True Range | 0.08 |
RSI (14) | 43.50 |
ADX | 37.26 |
+DI | 40.01 |
-DI | 14.95 |
Chandelier Exit (Long, 3 ATRs) | 0.18 |
Chandelier Exit (Short, 3 ATRs) | 0.44 |
Upper Bollinger Bands | 0.33 |
Lower Bollinger Band | 0.16 |
Percent B (%b) | 0.27 |
BandWidth | 69.92 |
MACD Line | -0.02 |
MACD Signal Line | -0.03 |
MACD Histogram | 0.0094 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.34 | ||||
Resistance 3 (R3) | 0.35 | 0.32 | 0.32 | ||
Resistance 2 (R2) | 0.32 | 0.29 | 0.32 | 0.31 | |
Resistance 1 (R1) | 0.27 | 0.27 | 0.25 | 0.25 | 0.30 |
Pivot Point | 0.24 | 0.24 | 0.23 | 0.23 | 0.24 |
Support 1 (S1) | 0.18 | 0.20 | 0.16 | 0.17 | 0.11 |
Support 2 (S2) | 0.15 | 0.18 | 0.14 | 0.11 | |
Support 3 (S3) | 0.09 | 0.15 | 0.10 | ||
Support 4 (S4) | 0.08 |